[go: up one dir, main page]

GB201307058D0 - Preparation and use of combination enzyme nd gastriontestinal modulator delivery systems - Google Patents

Preparation and use of combination enzyme nd gastriontestinal modulator delivery systems

Info

Publication number
GB201307058D0
GB201307058D0 GBGB1307058.6A GB201307058A GB201307058D0 GB 201307058 D0 GB201307058 D0 GB 201307058D0 GB 201307058 A GB201307058 A GB 201307058A GB 201307058 D0 GB201307058 D0 GB 201307058D0
Authority
GB
United Kingdom
Prior art keywords
gastriontestinal
preparation
delivery systems
combination enzyme
modulator delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB1307058.6A
Other versions
GB2497715A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curemark LLC
Original Assignee
Curemark LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curemark LLC filed Critical Curemark LLC
Publication of GB201307058D0 publication Critical patent/GB201307058D0/en
Publication of GB2497715A publication Critical patent/GB2497715A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GB1307058.6A 2010-11-19 2010-11-19 Preparation and use of combination enzyme and gastriontestinal modulator delivery systems Withdrawn GB2497715A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2010/057341 WO2012067621A1 (en) 2010-11-19 2010-11-19 Preparation and use of combination enzyme and gastrointestinal modulator delivery systems

Publications (2)

Publication Number Publication Date
GB201307058D0 true GB201307058D0 (en) 2013-05-29
GB2497715A GB2497715A (en) 2013-06-19

Family

ID=46084317

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1307058.6A Withdrawn GB2497715A (en) 2010-11-19 2010-11-19 Preparation and use of combination enzyme and gastriontestinal modulator delivery systems

Country Status (5)

Country Link
US (2) US20140147500A1 (en)
EP (2) EP2616048A4 (en)
CA (1) CA2815044A1 (en)
GB (1) GB2497715A (en)
WO (1) WO2012067621A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
EP2318035B1 (en) 2008-07-01 2019-06-12 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
KR101694931B1 (en) 2009-01-06 2017-01-10 큐어론 엘엘씨 Compositions and methods for the treatment or the prevention oral infections by e. coli
CN105664144B (en) 2009-01-06 2020-08-11 加尔纳根有限责任公司 Compositions and methods for treating or preventing staphylococcus aureus infections and eradicating or reducing staphylococcus aureus on surfaces
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
EP2705842A1 (en) * 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating parkinson's disease
WO2012145651A2 (en) 2011-04-21 2012-10-26 Curemark, Llc Compounds for the treatment of neuropsychiatric disorders
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
IN201611034271A (en) * 2016-10-06 2018-04-13 Delayed Release Pharmaceutical Composition Of Pantoprazole And Process For Preparation Thereof
EP3609528A4 (en) * 2017-04-10 2020-12-23 Curemark, LLC Compositions for treating addiction
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
KR102633592B1 (en) * 2021-04-23 2024-02-05 동국대학교 산학협력단 A Composition for preventing or treating Autism spectrum disorder and a method for treating ASD using thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE491927A (en) * 1948-10-30
US5618710A (en) * 1990-08-03 1997-04-08 Vertex Pharmaceuticals, Inc. Crosslinked enzyme crystals
US5190775A (en) 1991-05-29 1993-03-02 Balchem Corporation Encapsulated bioactive substances
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
KR19990072826A (en) * 1998-02-26 1999-09-27 우재영 A process for producing enteric-coated pancreatin granules
US6153236A (en) 1999-06-03 2000-11-28 Balchem Corporation Low melt encapsulation with high laurate canola oil
US6632429B1 (en) * 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US6534063B1 (en) 1999-12-17 2003-03-18 Joan M. Fallon Methods for treating pervasive development disorders
US6251478B1 (en) 1999-12-22 2001-06-26 Balchem Corporation Sensitive substance encapsulation
US6312741B1 (en) 2000-02-22 2001-11-06 Balchem Corporation Encapsulated food acids for preservation of baked goods
US6660831B2 (en) 2000-08-14 2003-12-09 Joan M. Fallon Method for diagnosing and treating dysautonomia and other dysautonomic conditions
IT1319655B1 (en) * 2000-11-15 2003-10-23 Eurand Int PANCREATIC ENZYME MICROSPHERES WITH HIGH STABILITY AND RELATIVE PREPARATION METHOD.
US6797291B2 (en) 2002-01-09 2004-09-28 Balchem Corporation Stable hygroscopic compositions and methods for stabilizing hygroscopic ingredients
US6616954B1 (en) 2002-03-14 2003-09-09 Balchem Corporation Solvent released encapsulated yeast
US6835397B2 (en) 2002-12-23 2004-12-28 Balchem Corporation Controlled release encapsulated bioactive substances
US8728521B2 (en) * 2005-12-27 2014-05-20 Hemant N. Joshi Physically/molecularly distributed and/or chemically bound medicaments in empty, hard capsule shells
DK2079445T3 (en) * 2007-02-20 2016-02-15 Allergan Pharmaceuticals Internat Ltd Stable digestive compositions
KR101694931B1 (en) * 2009-01-06 2017-01-10 큐어론 엘엘씨 Compositions and methods for the treatment or the prevention oral infections by e. coli
CN105664144B (en) * 2009-01-06 2020-08-11 加尔纳根有限责任公司 Compositions and methods for treating or preventing staphylococcus aureus infections and eradicating or reducing staphylococcus aureus on surfaces
US9056050B2 (en) * 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
TWI579589B (en) 2015-08-31 2017-04-21 中強光電股份有限公司 Wavelength conversion device and projector

Also Published As

Publication number Publication date
EP3056197A1 (en) 2016-08-17
EP2616048A4 (en) 2014-04-02
US20180243282A1 (en) 2018-08-30
US20140147500A1 (en) 2014-05-29
GB2497715A (en) 2013-06-19
WO2012067621A1 (en) 2012-05-24
CA2815044A1 (en) 2012-05-24
EP2616048A1 (en) 2013-07-24

Similar Documents

Publication Publication Date Title
GB201307058D0 (en) Preparation and use of combination enzyme nd gastriontestinal modulator delivery systems
GB2503861B (en) Enzyme delivery systems and methods of preparations and use
EP2413917A4 (en) Drug delivery system and methods of use
IL247595A0 (en) Novel modulators and methods of use
EP2648654A4 (en) Stent delivery systems and methods
ZA201301419B (en) Pharmaceutical composition and administrations thereof
SG10201601792UA (en) Novel modulators and methods of use
PL2643010T3 (en) Biologically active complex and its preparation
EP2563372A4 (en) Prebiotic formulations and methods of use
GB201104473D0 (en) Improved pharmaceutical compositions and methods of delivery
SG10201506031UA (en) St-246 liquid formulations and methods
ZA201104257B (en) Anchoring systems and methods of use thereof
GB201000907D0 (en) Anchorage systems and devices
IL221043A0 (en) Modified release formulation and methods of use
GB2477100B (en) Anchorage systems and devices
PL2538803T3 (en) Formulations and methods for nutrient delivery
GB2498667B (en) Construction of a pumping system and uses thereof
PT2521445T (en) Formulation and use thereof
EP2624854A4 (en) Moesin modulators and uses thereof
IL224191A (en) Formulations of 14 -epi-analogues of vitamin d and cmc
HUP1000407A2 (en) Ph dependent pulsatile and sustained release pharmaceutical composition
GB2484887B (en) Cultivation and dispensing of bacteria
HK40029301B (en) Enzyme delivery systems and methods of preparations and use
HK1190080B (en) Enzyme delivery systems and methods of preparations and use
HK1190080A (en) Enzyme delivery systems and methods of preparations and use

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)